{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:52:09Z","timestamp":1760921529586},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s11938-005-0030-z","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T17:45:28Z","timestamp":1180892728000},"page":"443-450","source":"Crossref","is-referenced-by-count":7,"title":["Hepatorenal syndrome"],"prefix":"10.1007","volume":"8","author":[{"given":"Bimaljit Singh","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"30_CR1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gines P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996, 23: 164\u2013176. Details the diagnostic criteria, predictive factors, and outcome of HRS","journal-title":"Hepatology"},{"key":"30_CR2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","volume":"20","author":"A Follo","year":"1994","unstructured":"Follo A, Llovet JM, Navasa M, et al.: Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20: 1495\u20131501.","journal-title":"Hepatology"},{"key":"30_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0016-5085(82)90129-9","volume":"82","author":"J Cabrera","year":"1982","unstructured":"Cabrera J, Arroyo V, Ballesta AM, et al.: Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982, 82: 97\u2013105.","journal-title":"Gastroenterology"},{"key":"30_CR4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1749-6632.1966.tb41223.x","volume":"139","author":"S Sherlock","year":"1966","unstructured":"Sherlock S, Walker JG, Senewiratne B, et al.: The complications of diuretic therapy in patients with cirrhosis. Ann N Y Acad Sci 1966, 139: 497\u2013505.","journal-title":"Ann N Y Acad Sci"},{"key":"30_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(79)90268-3","volume":"77","author":"TD Boyer","year":"1979","unstructured":"Boyer TD, Zia P, Reynolds TB: Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979, 77: 215\u2013222.","journal-title":"Gastroenterology"},{"key":"30_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0272-6386(87)80053-7","volume":"9","author":"GC Newell","year":"1987","unstructured":"Newell GC: Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987, 9: 183\u2013190.","journal-title":"Am J Kidney Dis"},{"key":"30_CR7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","volume":"328","author":"RJ Johnson","year":"1993","unstructured":"Johnson RJ, Gretch DR, Yamabe H, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993, 328: 465\u2013470.","journal-title":"N Engl J Med"},{"key":"30_CR8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","volume":"324","author":"KN Lai","year":"1991","unstructured":"Lai KN, Li PK, Lui SF, et al.: Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991, 324: 1457\u20131463.","journal-title":"N Engl J Med"},{"key":"30_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8: 1151\u20131157.","journal-title":"Hepatology"},{"key":"30_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2362.1979.tb01669.x","volume":"9","author":"V Arroyo","year":"1979","unstructured":"Arroyo V, Bosch J, Mauri M, et al.: Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979, 9: 69\u201373.","journal-title":"Eur J Clin Invest"},{"key":"30_CR11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199808203390807","volume":"339","author":"PY Martin","year":"1998","unstructured":"Martin PY, Gines P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339: 533\u2013341.","journal-title":"N Engl J Med"},{"key":"30_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/hep.1840020303","volume":"2","author":"H Ring-Larsen","year":"1982","unstructured":"Ring-Larsen H, Hesse B, Henriksen JH, et al.: Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 1982, 2: 304\u2013310.","journal-title":"Hepatology"},{"key":"30_CR13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.1984.99","volume":"25","author":"GF DiBona","year":"1984","unstructured":"DiBona GF: Renal neural activity in hepatorenal syndrome. Kidney Int 1984, 25: 841\u2013853.","journal-title":"Kidney Int"},{"key":"30_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0168-8278(01)00286-0","volume":"36","author":"J Uriz","year":"2002","unstructured":"Uriz J, Gines P, Ortega R, et al.: Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002, 36: 349\u2013355.","journal-title":"J Hepatol"},{"key":"30_CR15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0016-5085(87)90327-1","volume":"93","author":"A Rimola","year":"1987","unstructured":"Rimola A, Gavaler JS, Schade RR, et al.: Effects of renal impairment on liver transplantation. Gastroenterology 1987, 93: 148\u2013156.","journal-title":"Gastroenterology"},{"key":"30_CR16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","volume":"40","author":"T Restuccia","year":"2004","unstructured":"Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004, 40: 140\u2013146.","journal-title":"J Hepatol"},{"key":"30_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510270139","volume":"27","author":"BA Runyon","year":"1998","unstructured":"Runyon BA: Management of adult patients with ascites caused by cirrhosis. Hepatology 1998, 27: 264\u2013272.","journal-title":"Hepatology"},{"key":"30_CR18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1665-2681(19)32154-4","volume":"2","author":"A Cardenas","year":"2003","unstructured":"Cardenas A, Arroyo V: Hepatorenal syndrome. Ann Hepatol 2003, 2: 23\u201329.","journal-title":"Ann Hepatol"},{"key":"30_CR19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","volume":"94","author":"P Gines","year":"1988","unstructured":"Gines P, Tito L, Arroyo V, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94: 1493\u20131502.","journal-title":"Gastroenterology"},{"key":"30_CR20","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","volume":"350","author":"P Gines","year":"2004","unstructured":"Gines P, Cardenas A, Arroyo V, et al.: Management of cirrhosis and ascites. N Engl J Med 2004, 350: 1646\u20131654.","journal-title":"N Engl J Med"},{"key":"30_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2005.41381.x","volume":"100","author":"SK Baik","year":"2005","unstructured":"Baik SK, Jeong PH, Ji SW, et al.: Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005, 100: 631\u2013635.","journal-title":"Am J Gastroenterol"},{"key":"30_CR22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1572-0241.2004.40665.x","volume":"100","author":"C Villanueva","year":"2005","unstructured":"Villanueva C, Planella M, Aracil C, et al.: Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 2005, 100: 624\u2013630.","journal-title":"Am J Gastroenterol"},{"key":"30_CR23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0016-5085(03)00269-5","volume":"124","author":"G D\u2019Amico","year":"2003","unstructured":"D\u2019Amico G, Pietrosi G, Tarantino I, et al.: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003, 124: 1277\u20131291.","journal-title":"Gastroenterology"},{"key":"30_CR24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","volume":"20","author":"TH Kiser","year":"2005","unstructured":"Kiser TH, Fish DN, Obritsch MD, et al.: Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005, 20: 1813\u20131820.","journal-title":"Nephrol Dial Transplant"},{"key":"30_CR25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.CCM.0000128578.37822.F1","volume":"32","author":"MB Malay","year":"2004","unstructured":"Malay MB, Ashton JL, Dahl K, et al.: Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004, 32: 1327\u20131331.","journal-title":"Crit Care Med"},{"key":"30_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","volume":"33","author":"J Uriz","year":"2000","unstructured":"Uriz J, Gines P, Cardenas A, et al.: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000, 33: 43\u201348.","journal-title":"J Hepatol"},{"key":"30_CR27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","volume":"122","author":"R Moreau","year":"2002","unstructured":"Moreau R, Durand F, Poynard T, et al.: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122: 923\u2013930.","journal-title":"Gastroenterology"},{"key":"30_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","volume":"14","author":"C Halimi","year":"2002","unstructured":"Halimi C, Bonnard P, Bernard B, et al.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002, 14: 153\u2013158.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"30_CR29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","volume":"29","author":"A Hadengue","year":"1998","unstructured":"Hadengue A, Gadano A, Moreau R, et al.: Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998, 29: 565\u2013570.","journal-title":"J Hepatol"},{"key":"30_CR30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega R, Gines P, Uriz J, et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002, 36: 941\u2013948.","journal-title":"Hepatology"},{"key":"30_CR31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","volume":"18","author":"P Solanki","year":"2003","unstructured":"Solanki P, Chawla A, Garg R, et al.: Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003, 18: 152\u2013156.","journal-title":"J Gastroenterol Hepatol"},{"key":"30_CR32","first-page":"15","volume":"64","author":"JP Mulkay","year":"2001","unstructured":"Mulkay JP, Louis H, Donckier V, et al.: Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001, 64: 15\u201319.","journal-title":"Acta Gastroenterol Belg"},{"key":"30_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","volume":"27","author":"M Guevara","year":"1998","unstructured":"Guevara M, Gines P, Fernandez-Esparrach G, et al.: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27: 35\u201341.","journal-title":"Hepatology"},{"key":"30_CR34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","volume":"30","author":"V Gulberg","year":"1999","unstructured":"Gulberg V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999, 30: 870\u2013875.","journal-title":"Hepatology"},{"key":"30_CR35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","volume":"38","author":"G Pomier-Layrargues","year":"2003","unstructured":"Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003, 38: 238\u2013243.","journal-title":"Hepatology"},{"key":"30_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"WongF, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004, 40: 55\u201364. This study highlights the role of TIPS and vasoconstrictors in the treatment of HRS.","journal-title":"Hepatology"},{"key":"30_CR37","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P, Volpin R, Gerunda G, et al.: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29: 1690\u20131697.","journal-title":"Hepatology"},{"key":"30_CR38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1742-1241.1998.tb08933.x","volume":"52","author":"SM Lin","year":"1998","unstructured":"Lin SM, Lee CS, Kao PF: Low-dose dopamine infusion in cirrhosis with refractory ascites. Int J Clin Pract 1998, 52: 533\u2013536.","journal-title":"Int J Clin Pract"},{"key":"30_CR39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archinte.1975.00330070086014","volume":"135","author":"WM Bennett","year":"1975","unstructured":"Bennett WM, Keeffe E, Melnyk C, et al.: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975, 135: 964\u2013971.","journal-title":"Arch Intern Med"},{"key":"30_CR40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00003246-199501000-00031","volume":"23","author":"RJ Durkin","year":"1995","unstructured":"Durkin RJ, Winter SM: Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine. Crit Care Med 1995, 23: 202\u2013204.","journal-title":"Crit Care Med"},{"key":"30_CR41","first-page":"1053","volume":"36","author":"V Gulberg","year":"1998","unstructured":"Gulberg V, Luppa P, Pauletzki J, et al.: [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]. Z Gastroenterol 1998, 36: 1053\u20131058.","journal-title":"Z Gastroenterol"},{"key":"30_CR42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","volume":"36","author":"C Duvoux","year":"2002","unstructured":"Duvoux C, Zanditenas D, Hezode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002, 36: 374\u2013380.","journal-title":"Hepatology"},{"key":"30_CR43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(05)74933-3","volume":"353","author":"S Holt","year":"1999","unstructured":"Holt S, Goodier D, Marley R, et al.: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999, 353: 294\u2013295.","journal-title":"Lancet"},{"key":"30_CR44","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(96)91667-0","volume":"347","author":"CP Soper","year":"1996","unstructured":"Soper CP, Latif AB, Bending MR: Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996, 347: 1842\u20131843.","journal-title":"Lancet"},{"key":"30_CR45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM199401203300303","volume":"330","author":"M Rossle","year":"1994","unstructured":"Rossle M, Haag K, Ochs A, et al.: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994, 330: 165\u2013171.","journal-title":"N Engl J Med"},{"key":"30_CR46","first-page":"1766","volume":"25","author":"JR Lake","year":"1993","unstructured":"Lake JR, Ring E, LaBerge J, et al.: Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 1993, 25: 1766\u20131767.","journal-title":"Transplant Proc"},{"key":"30_CR47","first-page":"1169","volume":"90","author":"L Spahr","year":"1995","unstructured":"Spahr L, Fenyves D, N\u2019Guyen VV, et al.: Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 1995, 90: 1169\u20131171.","journal-title":"Am J Gastroenterol"},{"key":"30_CR48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004836-199504000-00016","volume":"20","author":"TM Sturgis","year":"1995","unstructured":"Sturgis TM: Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 1995, 20: 241\u2013243.","journal-title":"J Clin Gastroenterol"},{"key":"30_CR49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(97)24010-9","volume":"349","author":"KA Brensing","year":"1997","unstructured":"Brensing KA, Textor J, Strunk H, et al.: Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997, 349: 697\u2013698.","journal-title":"Lancet"},{"key":"30_CR50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","volume":"28","author":"M Guevara","year":"1998","unstructured":"Guevara M, Gines P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998, 28: 416\u2013422.","journal-title":"Hepatology"},{"key":"30_CR51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","volume":"47","author":"KA Brensing","year":"2000","unstructured":"Brensing KA, Textor J, Perz J, et al.: Long term outcome after transjugular intrahepatic portosystemic stentshunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000, 47: 288\u2013295. This study features the role of TIPS and vasoconstrictors in the treatment of HRS.","journal-title":"Gut"},{"key":"30_CR52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/lv.2000.6355","volume":"6","author":"SR Mitzner","year":"2000","unstructured":"Mitzner SR, Stange J, Klammt S, et al.: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000, 6: 277\u2013286.","journal-title":"Liver Transpl"},{"key":"30_CR53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341: 403\u2013409.","journal-title":"N Engl J Med"},{"key":"30_CR54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","volume":"119","author":"E Akriviadis","year":"2000","unstructured":"Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119: 1637\u20131648.","journal-title":"Gastroenterology"},{"key":"30_CR55","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","volume":"362","author":"P Gines","year":"2003","unstructured":"Gines P, Guevara M, Arroyo V, et al.: Hepatorenal syndrome. Lancet 2003, 362: 1819\u20131827.","journal-title":"Lancet"},{"key":"30_CR56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gines","year":"1993","unstructured":"Gines A, Escorsell A, Gines P, et al.: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105: 229\u2013236. Defines the diagnostic criteria, predictive factors, and outcome of HRS","journal-title":"Gastroenterology"},{"key":"30_CR57","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","volume":"17","author":"I Colle","year":"2002","unstructured":"Colle I, Durand F, Pessione F, et al.: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002, 17: 882\u2013888.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-005-0030-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0030-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:16:41Z","timestamp":1707938201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-005-0030-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s11938-005-0030-z","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}